| Ticker Details |
REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy.
|
| IPO Date: |
September 17, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$707.66M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.80 | 3.20%
|
| Avg Daily Range (30 D): |
$0.50 | 4.39%
|
| Avg Daily Range (90 D): |
$0.47 | 4.79%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.43M |
| Avg Daily Volume (30 D): |
1.34M |
| Avg Daily Volume (90 D): |
1.56M |
| Trade Size |
| Avg Trade Size (Sh.): |
74 |
| Avg Trade Size (Sh.) (30 D): |
72 |
| Avg Trade Size (Sh.) (90 D): |
81 |
| Institutional Trades |
| Total Institutional Trades: |
3,537 |
| Avg Institutional Trade: |
$1.9M |
| Avg Institutional Trade (30 D): |
$1.53M |
| Avg Institutional Trade (90 D): |
$1.42M |
| Avg Institutional Trade Volume: |
.08M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.12M |
| Avg Closing Trade (30 D): |
$1.6M |
| Avg Closing Trade (90 D): |
$1.59M |
| Avg Closing Volume: |
86.25K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$-3.78
|
$.43
|
$-1.72
|
|
Diluted EPS
|
$-3.78
|
$.43
|
$-1.72
|
|
Revenue
|
$174.48M
|
$108.02M
|
$6.39M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-196.43M
|
$22.71M
|
$-90.05M
|
|
Operating Income / Loss
|
$-164.15M
|
$29.26M
|
$-83.36M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$-43.07M
|
$21.26M
|
$-19.24M
|
|
PE Ratio
|
|
|
|
|
|
|
